Market Exclusive

ATRICURE, INC. (ATRC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ATRICURE, INC. (ATRC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective November 11, 2016,  the Board of Directors (the “Board”) of AtriCure, Inc. (the “Company”) appointed Sven Wehrwein to serve as a Director until the next Annual Meeting of Stockholders.  The Board has determined that Mr. Wehrwein is an independent director in accordance with guidelines that the Company has adopted, which guidelines comply with the listing standards set forth by The NASDAQ Stock Market. Mr. Wehrwein also has been appointed to the Board’s Audit Committee.

Mr. Wehrwein has been an independent financial consultant to emerging companies since 1999. He has more than 35 years of experience as an investment banker, chief financial officer, and certified public accountant. Wehrwein currently sits on the boards of several companies, including Proto Labs, Inc. and SPS Commerce, Inc. In addition, he has served as a Director for a number of other medical device and high growth companies including tenures on the boards of Compellent Technologies, Synovis Life Technologies, and Vital Images.

There is no arrangement or understanding between Mr. Wehrwein and any other person to which Mr. Wehrwein was appointed as a Director of the Company, and there have been no transactions nor are there any proposed transactions between the Company and Mr. Wehrwein that would require disclosure to Item 404(a) of Regulation S-K. Mr. Wehrwein will receive compensation for his service as a director in accordance with the Company’s compensation policies for non-employee directors, which are described under the heading “Director Compensation” in the Company’s proxy statement filed with the SEC on April 15, 2016.

A copy of the press release announcing Mr. Wehrwein’s appointment is furnished as Exhibit 99.1 and incorporated by reference in this Item 5.02.

Item 9.01Financial Statements and Exhibits.

(d)  Exhibits

No.Description

99.1Press Release dated November 11, 2016

About ATRICURE, INC. (ATRC)

Exit mobile version